Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | SLC9A3 | P48764 | 5/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899001 | 1.00 | NPC1 (0.35) | NPC1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL12922732 | 0.88 | ALDH1A1 (0.32) | NPC1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL4898991 | 0.86 | SLC9A3 (0.36) | SLC9A3 | |
| SCHEMBL12922737 | 0.81 | CHRM3 (0.38) | SLC9A3 | |
| SCHEMBL4028962 | 0.79 | SLC9A3 (0.46) | SLC9A3 | |
| SCHEMBL978750 | 0.78 | SLC9A3 (0.39) | SLC9A3 | |
| SCHEMBL979823 | 0.78 | SLC9A3 (0.39) | SLC9A3 | |
| SCHEMBL977579 | 0.78 | SLC9A3 (0.32) | SLC9A3 | |
| SCHEMBL977578 | 0.78 | SLC9A3 (0.32) | SLC9A3 | |
| SCHEMBL979244 | 0.77 | SLC9A3 (0.33) | SLC9A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058328-A1 | SUBSTITUTED 4-PHENYLTETRAHYDROISOQUINOLINES, PHARMACEUITCAL COMPOSITIONS COMPRISING THEM AND THERAPEUTIC METHODS FOR THEIR USE | REN, MTNR1B, MTNR1A | NPC1 238/4885GAA 3127/4885MAPT 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.